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ABSTRACT
Objectives Care of patients with motor neuron 
disease (MND) in a specialist, multidisciplinary clinic 
is associated with improved survival, but access is 
not universal. We wanted to pilot and establish the 
feasibility of a deinitive trial of a novel telehealth system 
(Telehealth in Motor neuron disease, TiM) in patients 
with MND.
Design An 18-month, single-centre, mixed-methods, 
randomised, controlled pilot and feasibility study.
Intervention TiM telehealth plus usual care versus usual 
care.
Setting A specialist MND care centre in the UK.
Participants Patients with MND and their primary 
informal carers.
Primary and secondary outcome 
measures Recruitment, retention and data collection 
rates, clinical outcomes including participant quality of life 
and anxiety and depression.
Results Recruitment achieved the target of 40 
patients and 37 carers. Participant characteristics 
relected those attending the specialist clinic and 
included those with severe disability and those with 
limited experience of technology. Retention and data 
collection was good. Eighty per cent of patients and 
82% of carer participants reported outcome measures 
were completed at 6 months. Using a longitudinal 
analysis with repeated measures of quality of life 
(QoL), a sample size of 131 per arm is recommended 
in a deinitive trial. The methods and intervention were 
acceptable to participants who were highly motivated to 
participate to research. The low burden of participation 
and accessibility of the intervention meant barriers 
to participation were minimal. However, the study 
highlighted dificulties assessing the associated costs 
of the intervention, the challenge of recruitment in such 
a rare disease and the dificulties of producing rigorous 
evidence of impact in such a complex intervention.
Conclusion A deinitive trial of TiM is feasible but 
challenging. The complexity of the intervention and 
heterogeneity of the patient population means that a 
randomised controlled trial may not be the best way to 
evaluate the further development and implementation of 
the TiM.
Trial registration number ISRCTN26675465.
BACkgROunD
Motor neuron disease (MND) is an incur-
able, neurodegenerative disease that causes 
progressive muscle paralysis, limb weakness, 
breathing, speech and swallowing difficulties 
leading to death after, on average, 2–4 years 
from symptom onset.1 Riluzole, non-invasive 
ventilation (NIV) and possibly edaravone 
only offer small survival benefits.2–4 Atten-
dance at a specialist MND multidisciplinary 
clinic (MDC) is associated with improved 
survival and increased use of proven thera-
pies.5–10 The aim of specialist MND care is to 
maximise survival and QoL by providing coor-
dinated, patient-centred care to address the 
biopsychosocial needs of patients and their 
families.11 It is recommended that the MDC 
should monitor patients regularly to detect 
and treat complications quickly.12 13 However, 
patients become progressively more disabled 
and travelling to clinic becomes difficult or 
impossible. Even in developed countries, 
attendance at MDCs varies (between 43% 
and 85%) and many of those who do see a 
Strengths and limitations of this study
 Ź This is the irst study of the feasibility of this digitally 
enabled care system for patients and carers living 
with motor neuron disease.
 Ź The trial methods and intervention enabled patients 
with signiicant disabilities to participate.
 Ź The qualitative data collection aimed to identify key 
barriers and enablers to participation in clinical tri-
als of telehealth and motor neuron disease from the 
perspective of patients, carers and nurses.
 Ź This was a study with a small number of patients in 
a single centre.
 Ź It was not possible to fully assess the impact of 
the intervention on the clinical service’s stafing or 
healthcare resource use.
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specialist are unable to return.14 The disease is rare (a 
worldwide prevalence of 5.40 per 100 00015) meaning 
there are few specialist centres and general clinicians 
have limited experience of caring for patients with MND. 
This makes accessing the right care at the right time diffi-
cult leading to significant distress.16–21 There is therefore 
a great need to improve access to specialist MND care.
We developed the Telehealth in Motor neuron disease 
(TiM) system: a digitally enabled care system using tele-
health to enable patients and their informal carers to 
report their progress and symptoms from their homes.22 
We hypothesised that improving access to specialist care 
may result in earlier identification and management of 
complications thus improving QoL and survival. We 
thought the TiM system could improve care coordination 
and result in better prioritisation of health resource use, 
thereby reducing costs or increasing service capacity. The 
TiM was developed using a process of user-centred code-
sign22 but further piloting of such a complex intervention 
was required.23
Telehealth is a complex intervention that consists 
of different component parts (such as the software, 
the context and behaviours of those who use it) whose 
success depends on these interacting factors.23 Clinical 
trials of telehealth face various challenges including diffi-
culties with recruitment, staff engagement and difficulties 
capturing the important impacts of the intervention.24–26 
Furthermore, MND trials tend to recruit an unrepre-
sentative sample of patients (on average younger, male 
patients with longer survival).27 This may be explained, in 
part, due to the many barriers to participation including 
the need to travel to study centres, and the small number 
of geographically dispersed patients who may be frail 
or deteriorating rapidly. The Medical Research Council 
(MRC) Framework for Developing and Evaluating 
Complex Interventions highlights the importance of 
feasibility and piloting of the study methods to ensure the 
definitive trial will overcome these barriers.23
Aims of the study
We wanted to pilot the methods and evaluate the feasi-
bility of conducting a definitive randomised controlled 
trial (RCT) of the TiM in patients and carers versus 
usual care. We aimed to use low-burden, pragmatic study 
methods that could recruit and retain a representative 
sample of all patients with MND. The feasibility outcomes 
examine recruitment, retention and data collection. The 
study also aimed to provide an understanding of the 
resources required to conduct a definitive trial including 
staff burden and an estimation of variation in outcomes 
in order to provide a more accurate predictor of sample 
size. Online supplementary file 1 describes the feasibility 
questions using A process for Decision-making after 
Pilot and feasibility Trials (ADePT) framework28. We also 
explored factors that may influence these outcomes and 
also whether the outcomes measures effectively assessed 
aspects of life with MND and the impact of the TiM.
We also conducted a process evaluation of the TiM 
to understand how the system was used and to identify 
some of the potential impacts of the TiM on participants, 
carers and the MND service. This is reported in a parallel 
publication.29
MeThODS
Study design
This was a single-centre, unblinded, randomised, 
controlled pilot and feasibility trial of usual MND care 
versus the TiM plus usual care. Usual care involves invi-
tations to the MDC clinic every 2–6 months and access 
to the MDC between times via the specialist nurse. The 
protocol and statistical analysis plan are available in 
online supplementary file 2.
Patient and public involvement
In addition to the user-centred design process used to 
develop the TiM22 during development of the interven-
tion and the protocol we consulted patients, carers and 
the Sheffield MND Research Advisory group (a patient 
and public involvement group). They reviewed the inter-
vention, principles of the trial, trial design, outcome 
measures and participant information leaflets and 
provided comments on their feasibility and accessibility. 
They were not involved in recruitment. Results of the 
study have been communicated at various public meetings 
through the Sheffield MND Research Advisory group and 
local branch of the MND Association and a lay summary 
will be circulated. Members of this group attended the 
trial steering and trial management groups. AQ was a 
member of the trial management group, provided advice 
on the research methods, interpretation of the data and 
dissemination and is a coauthor on this paper.
Recruitment
We prescreened patients using a clinical database of 
patients attending the Sheffield MDC. We determined the 
order of invitation using a list of random numbers gener-
ated using Excel. When the pool of prevalent patients 
was exhausted, we invited all newly diagnosed patients. 
We invited patients and their primary informal carer to 
participate by letter including a prepaid return slip. Eligi-
bility was confirmed and written/witnessed verbal consent 
was obtained at all research visits and data collection was 
conducted in participants’ homes. This approach meant 
patients who were not currently attending the MDC (due 
to frailty or geography) were able to participate.
eligibility criteria
We included adult patients receiving care from the Shef-
field MDC, living within 2 hours’ drive from Sheffield. 
Initially the diagnostic inclusion criteria were those with 
a diagnosis of clinically definite or probable amyotrophic 
lateral sclerosis (ALS) according to the El Escorial 
Criteria.30 However, prior to recruitment commencing, 
a review of 200 patients on the MDC database found 
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that 58% of patients would be excluded based on these 
criteria: 38% of patients had ALS but did not fulfil the 
El Escorial Criteria at their last assessment30 and 21% 
of patients had atypical MND (primary lateral sclerosis 
(PLS), progressive muscular atrophy (PMA) or an uncat-
egorised progressive ALS/MND illness). We felt many 
of these patients not fulfilling the strict criteria would 
benefit from better MDC care and so we modified the 
criteria to include all patients with ALS with symptom 
onset within the last 3 years. We also included all patients 
diagnosed with any type of MND (ALS, PLS, PMA) who 
had evidence of progression in their condition (an indi-
cator that they may require MDC monitoring and care) as 
evidenced by a deterioration in the Amyotrophic Lateral 
Sclerosis Functional Rating Scale-Revised (ALSFRS-R)31 
of at least two points during the previous 18 months (a 
small but meaningful change).
We excluded patients attending another MDC, those 
unwilling to allow their carer to operate the TiM on their 
behalf if they could not do it themselves and those with 
no form of telephone or internet access. Patients had the 
option of identifying their primary informal carer who 
was then invited to participate as a carer and consented. 
Eligible informal carers were adults who were the patients’ 
main provider of unpaid care. Initially, patients could 
participate only if their carer consented to be involved. 
Later we changed the criteria to allow patients to partici-
pate without a carer.
Randomisation
Patients were randomised 1:1 after recruitment to receive 
usual care or TiM using www. sealedenvelope. com which 
employs permuted block randomisation with a mixture of 
block sizes (block size concealed). Stratification was not 
employed.
Intervention
A detailed description of the TiM has been published.22 
The use of the TiM in this trial is described in detail in 
the parallel publication describing the process evalua-
tion.29 In brief patients and carers were asked to complete 
weekly sessions answering questions about their condi-
tion (such as functional ability, symptoms, depression and 
anxiety symptoms, carer strain) and patients recorded 
their weight and balance. The results could be viewed on 
a website by the MND nurse at the specialist care centre. 
She could take actions including telephoning the patient/
carer, expediting clinic appointments or liaising with the 
multidiscipliary team. She could not delay appointments 
or make clinical decisions without checking the accu-
racy of the information with the patient, carer or clinical 
team. All participants were shown how to use the TiM app 
during recruitment and the presence of any difficulties 
using the system was recorded.
Data collection
Patient/carer-reported outcome measures (PROM) were 
completed at home during the baseline study visit and 
at 3, 6, 12 and 18 months using postal questionnaires. 
Generic and MND-specific PROMs captured QoL, MND 
clinical outcomes, survival and health resource use. 
Adverse events were recorded using PROMs and during 
MDC visits. We created a ‘Shadow Monitoring Protocol’ 
where the MND physician would review the TiM data and 
complete a questionnaire 2 weeks prior to MDC appoint-
ments and again at each appointment. Physicians were 
asked to respond to agree/disagree statements assessing 
their opinion on the accuracy and acceptability of the 
TiM answers and whether it may be possible to use the 
information to make decisions without seeing the patient 
(see online supplementary file 2; p 71). Telehealth nurse 
activity was also collected using a 2-week diary, twice in the 
trial. After the trial we downloaded all data in TiM system 
into Excel.
We conducted 56 semistructured participant inter-
views (characteristics are described in full in online 
supplementary file 3). Control participants were inter-
viewed at baseline (17 interviews) and intervention 
participants were interviewed at 1 and 6 months (20 
at 1 month and 19 interviews at 6 months). Most inter-
views were face to face at home with patients and carers 
together, but telephone and email were also used. Inter-
views were also conducted with the telehealth nurse 
(at months 4 and 14) and a community nurse (month 
18). Topic guides were used (see online supplementary 
file 2 pp 41–44) and field notes taken during and after 
the interview. Interviews were audio recorded and tran-
scribed verbatim. Early results and observations during 
the trial informed later interviews. As new themes 
were being identified later in the research study, we 
attempted to interview all participants and by the end 
of the study no new themes were identified. To eval-
uate the feasibility of the study, participants were asked 
about their attitudes towards research. To evaluate the 
validity and acceptability of the PROMs, control partic-
ipants also performed a ‘think-aloud’ task during which 
they were asked to complete the baseline PROMs and 
describe their reactions. To explore the feasibility and 
acceptability of digitally enabled care, participants and 
clinicians were asked about their attitudes towards tech-
nology, the TiM system and MND care.
Outcomes
The trial assessed the following feasibility outcomes:
 Ź Trial processes: rates of eligibility, recruitment, reten-
tion and completion of postal questionnaires.
 Ź Use of the intervention: frequency of use of TiM 
by participants (collected automatically by the TiM 
system), participant satisfaction with TiM (question-
naires) and telehealth nurse time using TiM using 
two fortnight diaries (see parallel paper for additional 
results).29
In addition, clinical outcomes (listed in tables 1 and 2) 
were collected to test trial procedures and as indicative 
parameters to inform the sample size of a full-scale trial.
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Table 1 Patient outcome measures collected
Baseline*
Postal questionnaires
Clinic visitsBaseline 3 months 6 months 12 months 18 months
Patient characteristics
  Age, gender X             
  Frequency of technology 
use
X             
  Broadband/mobile internet 
access
X             
  Presence of dificulties 
using TiM
X             
  Need for help using TiM X             
Medical history
  Diagnosis   X           
  Disease duration   X           
  Comorbidities   X           
  Drug history   X           
Quality of life
  ALSAQ-40   X X X X X   
  RAND-36   X X X X X   
  EQ-5D+D   X X X X X   
Clinical measures
  ALSFRS-R   X X X X X   
  Pain score (current and 
worst)†
  X X X X X   
  CSS-MND   X X X X X   
  Hospital Anxiety and 
Depression score
  X X X X X   
  Survival             X
  Adverse events     X X X X X
Health resource use
  Clinician encounters†   X X X X X X
  Hospital admissions†   X X X X X X
  Informal care use†   X X X X X   
  Formal care use†   X X X X X   
Satisfaction
  MND care satisfaction†   X X X X X   
  TiM satisfaction†     X‡ X‡ X‡ X‡   
*Collected by investigator.
†Questionnaires designed for the trial.
‡Intervention arm only.
ALSAQ-40, 40-item Amyotrophic Lateral Sclerosis Assessment Questionnaire; ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating 
Scale-Revised; CSS-MND, Clinical Saliva Scale for Motor Neuron Disease; EQ-5D+D, EQ-5D + dignity bolt-on; MND, motor neuron disease; 
RAND-36, Rand 36-Item Health Survey; TiM, Telehealth in Motor neuron disease.
Blinding, bias and study conduct
It was not possible to blind the patients or investigators 
to treatment allocation and EVH had involvement in 
some patients’ clinical MDC visits. Measures to reduce 
bias were used. The role of EVH as an investigator and 
her involvement in the TiM development was explained 
at each visit and any clinical queries were passed onto the 
telehealth nurse. Follow-up PROMs were completed by 
participants independently at home and entered by an 
independent study nurse. Quantitative analysis was over-
seen by the study statistician using a prespecified analysis 
plan. Data triangulation (qualitative, TiM use, trial data) 
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Table 2 Carer outcome measures collected
Baseline*
Postal questionnaires
Clinic visitsBaseline 3 months 6 months 12 months 18 months
Carer characteristics
Age, gender X
Relationship to 
patient
X
Frequency of 
technology use
X
Presence of 
dificulties using 
TiM
X
Quality of life
RAND-36 X X X X X
Clinical measures
Hospital Anxiety 
and Depression 
score
X X X X X
Zarit Burden 
Interview
X X X X X
Adverse events X X X X X
MND care 
satisfaction†
X X X X X
TiM satisfaction† X‡ X‡ X‡ X‡
*Investigator completed.
†Questionnaires designed for the trial.
‡Intervention arm only.
MND, motor neuron disease; RAND-36, Rand 36-Item Health Survey; TiM, Telehealth in Motor neuron disease.
and methodological triangulation (patients, carers, staff) 
were employed. EVH conducted all the interviews except 
the 14-month interview with the telehealth nurse which 
was conducted by coauthor WOB (an experienced qual-
itative researcher independent of the clinical team) who 
also oversaw the interview planning, conduct and analysis.
Analysis
Quantitative data were analysed using descriptive statis-
tics and qualitative data were organised using NVivo32 
and analysed using thematic analysis.33 A triangulation 
process compared the quantitative and qualitative data to 
further understand and explain important, incongruent 
and unexpected observed phenomenon. Early results 
provided some insight into how the TiM was being used 
and informed changes to the intervention and study 
methods.
Sample size
A target of 40 patients and 40 carers was selected to enable 
an estimation of the SD of potential outcome measures to 
within a precision of ±20% of its true underlying value 
with 90% confidence.34 The sample size was also based 
on guidance that a minimum of 12 evaluable patients 
per trial arm is required (ie, after allowing for death, 
withdrawal or dropout) in order to inform a sample size 
calculation for a definitive trial.34 35
Role of the funding sources
The TiM was developed through a collaboration between 
the University of Sheffield, Sheffield Teaching Hospitals 
NHS Trust, Mylan and Abbott Healthcare Products Ltd. 
This trial was funded by the National Institute for Health 
Research and the Motor Neurone Disease Association. 
Mylan supplied software, hardware and some technical 
expertise. The telehealth nurse took on the additional 
duties as part of her current role. The study design, 
conduct, analysis, and interpretation of data, writing of 
the report, and the decision to submit the paper for publi-
cation were conducted by the authors independently of 
the funders with the exception of a requirement to report 
adverse events the investigator deemed to be related to 
Abbott Healthcare’s pharmaceuticals.
ReSulTS
A summary of the feasibility questions using the ADePT 
framework28 is presented in the online supplementary file 
1 . Qualitative data are reported within each section to 
explain the findings. Online supplementary file 3 contains 
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Figure 1 Consolidated Standards of Reporting Trials 
(CONSORT) low diagram. Follow-up varied depending on 
when patients entered the study ranging from 18 months (for 
those recruited at the start of recruitment period) to 6 months 
for those recruited at the end of the recruitment period. At 
each time point patients are either reported as reached the 
time point (analysed) or had died, withdrawn or did not reach 
that time point due to being recruited later in the study. 
ARC database, the database of living patients with MND 
receiving/having received care at the Shefield MDC; MCD, 
multidisciplinary clinic.
the results of each outcome measure and supporting 
qualitative quotes (online supplementary file 3).
Screening and eligibility
Three hundred and six patients were prescreened 
(figure 1). One hundred and twenty-three patients (40%) 
were excluded because the Sheffield MDC was not their 
main or current care centre. Of the remaining 183, eighty-
eight patients were excluded on clinical grounds, mainly 
due to lack of disease progression or cognitive impair-
ment. This left 95 eligible patients (52% of the patients 
attending the MDC).
Recruitment
Forty-two patients (44%) expressed an interest in partic-
ipating. Forty (42%) were eligible: 28 prevalent and 
12 incident cases. All 40 were consented, randomised 
and received the intervention between October 2014 
and November 2015. Thirty-seven eligible carers were 
recruited. Three patients were recruited who did not 
have a primary carer.
Participant characteristics
Age, gender, phenotype and site of onset were similar to 
a much larger cohort of patients at the Sheffield MDC7 
(table 3). Age ranged from 30 to 78 years and participants 
had disabilities ranging from mild to severe, including 13 
(33%) who used either NIV or a gastrostomy tube (King’s 
stage 436).
Barriers and enablers to recruitment
Interviews indicated that recruitment and randomisation 
were acceptable and participants understood the prin-
ciples of the study and were willing to be randomised. 
Some participants thought that the TiM would simply 
function to collect research data, rather than to facilitate 
MDC care. Participants wanted to participate because 
they liked the concept of telehealth and because they 
were highly motivated to participate in research. They 
expressed a strong altruistic desire to help others and to 
help the clinical team. Participation made patients feel 
they still had a valuable contribution to make, even when 
severely disabled:
I love being part of something worthwhile. (Patient 
229)
Participants thought they might gain benefit by learning 
more about the condition, to improve their chances of 
taking part in a treatment trial and to have increased 
contact with the MND team. Some kept up to date with 
information on the internet and many expressed frus-
tration about the speed of research and felt time was 
running out for them to be cured. They all wanted to see 
treatments that had tangible benefits.
…it doesn’t have to cure you it just has to make things 
better. (Carer 232)
Participants wanted to learn about research as this 
provided hope. Patients thought trials would be ‘safe’ if 
they involved a doctor whom they trusted but also recog-
nised that information could be unreliable and offer ‘false 
hope’. A small number were willing to use unproven ther-
apies or take part in trials even if they had potential for 
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Table 3 Participant characteristics
Telehealth
n=20
Control
n=20
Gender male 14 (70%) 14 (70%)
Age (years)
Mean (SD), range
60.4 (11.7), 
30–78
60.0 (10.0), 
39–73
Phenotype
  Amyotrophic lateral 
sclerosis
17 (85%) 18 (90%)
  Primary lateral sclerosis 2 (10%) 2 (10%)
  Progressive muscular 
atrophy
1 (5%) 0 (0%)
Disease duration (months)
  Mean (SD), range 53 (48), 12–197 46 (35), 7–123
Duration since diagnosis (months)
  Mean (SD), range 32 (34), 3–137 21 (19), 1–58
King’s ALS clinical stage*
  1 3 (15%) 2 (10%)
  2 4 (20%) 5 (25%)
  3 5 (25%) 8 (40%)
  4 8 (40%) 5 (25%)
Use of the TiM app
  Independently 17 (85%) 17 (85%)
  Assistance from carer 1 (5%) 1 (5%)
  Patient instructs carer 2 (10%) 2 (10%)
Technology use†
  Daily 14 (70%) 18 (90%)
  A few times per week 3 (15%) 1 (5%)
  Once a week 1 (5%) 1 (5%)
  Every few weeks 0 (0%) 0 (0%)
  Never 2 (10%) 0 (0%)
Home technology
  Broadband 18 (90%) 20 (100%)
  3G mobile reception 18 (90%) 15 (75%)
 
Telehealth
n=18
Control
n=19
Carer gender male 4 (21%) 5 (28%)
Carer age (years)
  Mean (SD), range
59 (12), 42–84 60.8 (11), 38–73
Relationship to patient     
  Partner 18 (95%) 16 (89%)
  Child 0 (0%) 1 (6%)
  Parent 1 (5%) 1 (6%)
Carer technology use†
  Daily 12 (67%) 16 (84%)
  A few times per week 1 (6%) 1 (5%)
  Once a week 1 (6%) 1 (5%)
  Every few weeks 0 (0%) 0 (0%)
  Never 4 (22%) 0 (0%)
Continued
 
Telehealth
n=18
Control
n=19
*King’s stage 1 refers to patients with functional deicit in 
one domain, stage 2: two domains, stage 3: three domains, 
stage 4: patients requiring non-invasive ventilation (NIV) and/
or gastrostomy.36 King’s stage was calculated using the 
Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised 
(ALSFRS-R) scale at baseline.
†Technology: computer, smartphone, tablet.
ALS, amyotrophic lateral sclerosis; TiM, Telehealth in Motor 
neuron disease.
Table 3 Continued
significant harm in order to gain an opportunity to be 
cured as they felt they had ‘have nothing to lose’.
Retention
To maximise the experience gained using the TiM, all 
participants remained in the study until they died or the 
study finished in April 2016. Follow-up ranged from 6 to 
18 months. Two patients (5%) who were severely disabled 
at recruitment felt too ill to continue. No carers withdrew 
and no participants were lost to follow-up.
The factors that facilitated study participation were the 
low burden of the study and the intervention (completed 
at home, minimal visits and a clear understanding of 
what would be expected of them). Participants identi-
fied barriers posed by other clinical trials such as fatigue, 
burden or disruption of family life but stated these 
were not experienced in this study. Carers did not want 
research that required them to be removed from their 
caring duties.
My care’s here. I can’t have anything that takes it away 
from what I’m doing with P. It’s got to be very simple 
things. I can sit with my iPad and I can fill in a ques-
tionnaire. (Carer 184)
Adherence to the intervention
Detailed description of the acceptability, use of and adher-
ence to the intervention is described in the parallel publica-
tion.29 In brief: compliance was high with 14 (70%) patients 
completing a TiM session, on average, fortnightly and 13 
(70%) carers completing at least three weekly sessions.
Feasibility and validity of the participant-reported outcome 
measures
Adherence to the postal questionnaires was good. At 6/12 
months 80%/71% of patients and 82%/67% of carer 
questionnaires were returned. Both treatment groups had 
similar completion rates. Participants felt the PROMs were 
accessible and not burdensome. They welcomed a thor-
ough assessment of all aspects of life with MND and iden-
tified PROMs examining their emotional health and carer 
strain as the best assessment of their experiences of MND.
To be quite frank, doctor, I wouldn't care a mon-
key's what you ask …I have no hang-ups about any 
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questions, however personal, the team think it's nec-
essary to ask. (Carer 229)
Most PROMs were returned complete but 2% of the 
Rand 36-Item Health Survey (RAND-36) questionnaires 
were incomplete and participants felt the statements 
posed in the RAND-36 were too subjective and did not 
reflect the experiences of life as a carer or patient with 
MND. Patients and carers found it difficult to answer ques-
tions referring to ‘health’: some thought they were entirely 
healthy or did not perceive MND to be a ‘health’ problem. 
Participants favoured the MND-specific QoL question-
naire (40-item Amyotrophic Lateral Sclerosis Assessment 
Questionnaire, ALSAQ-40), preferring the format and 
content. It was observed that the language used in the 
ALSAQ-40 closely reflected the language patients used 
to describe their experiences. Patients found it difficult 
to report the number of informal hours of care they 
received per week. Nine per cent of these questions were 
blank. There was a large variation in informal carer hours 
required (0–168 hours/week) with no clear relationship 
between a patient’s disability and hours of care. Couples’ 
roles had gradually changed as carers took over many of 
the domestic jobs that were usually shared. This made it 
difficult to quantify how much of their role was ‘caregiving’. 
Some carers explained that even if they were not directly 
providing care they always had to be alert to the needs 
of their loved one and so many patients wrote that they 
required care ‘24×7’. In addition, the questionnaire did 
not record multiple carers or where professional carers 
took over the role of an informal carer.
Feasibility of other data collection methods
The telehealth nurse diaries were returned incomplete. 
The nurse reported that it was difficult to assess her time 
using the TiM because she was often doing multiple tasks 
making it difficult to determine whether the time spent 
on an activity was part of ‘usual care’ or triggered by a TiM 
session. The Shadow Monitoring Protocol planned for 
clinicians to review information on the TiM and provide 
feedback prior to clinic. This was found to be infeasible 
because clinic appointments were frequently rescheduled 
or not booked sufficiently far in advance. There were 
administrative difficulties accessing the paper records 
(electronic records were not used during the trial). 
However, after the MDC clinic, physicians completed 
38 Shadow Monitoring feedback forms about the TiM, 
although total clinic numbers were not collected so 
compliance with this form could not be measured.
Outcome assessment
All clinical outcomes are reported in the online supple-
mentary file 3. Adverse events were low and none directly 
caused by the TiM system. We did not compare treatment 
arms in this feasibility study. However, we examined the 
data to determine whether it was possible to capture the 
impact of the TiM on MND outcomes. It is expected that 
over 6–12 months most patients with MND deteriorate 
in a meaningful way and therefore this change should 
be captured by our outcome measures. The ALSFRS-R 
confirms this as scores declined at a similar rate to the 
MDC population indicating disease progression (0.39 
points per month compared with 0.34 per month recorded 
in the Sheffield MDC clinic).7 Physical QoL showed a 
trend towards deterioration in both the RAND-36 and 
the physical subscores of the participants’ preferred QoL 
measure the ALSAQ-40. The incidence of severe anxiety 
in carers also increased. Mostly these changes were small 
and did not reach significance but the sample sizes were 
too small to draw firm conclusions. Measuring health 
economic data identified a number of difficulties: only 
four hospital admissions were reported during the whole 
trial and other health resource use was highly variable. 
For example, between the third and sixth months of the 
trial healthcare visits ranged from 0 to 121 (intervention: 
median 8, range 0–121; control: median 4, range 2–17). 
The number of encounters did not appear to be related 
to patient satisfaction or access to MND services: some 
patients who reported to receive excellent, coordinated 
care had very few appointments whereas other patients 
reporting good care had many appointments.
Sample size for a full RCT
The sample size for a full-scale trial depends on the type I 
and II errors, the level of missing data due either to death 
or withdrawal and the anticipated size of effect. Assuming 
a 5% level of statistical significance, 90% power and 75% 
follow-up (based on the number completing 12-month 
follow-up in this study) and an effect size of 0.3 SD, a stan-
dard sample size calculation requires a prohibitive 312 
patients per trial arm. This number can be reduced by 
employing a longitudinal approach to the analysis which 
the repeated measures (in this study the baseline, and 3, 
6 and 12 months) are used in a repeated measures regres-
sion.37 Adopting this approach to the above scenario and 
assuming a correlation of 0.5 between measures leads to a 
more achievable sample size of 131 per arm. The sample 
size could be reduced further if a larger effect size was 
used (a 0.4 SD effect size requires 74 patients per arm), 
although larger effect sizes seem unlikely for a non-dis-
ease-modifying intervention. On the other hand, smaller 
effect sizes would be unjustified given the cost and service 
redesign requirements associated with implementation. 
We also note the present study is limited by its size, thus 
precluding a reliable estimate of whether the postulated 
effect sizes are reasonable.
DISCuSSIOn
The aim of the study was to determine the feasibility and 
acceptability of conducting an RCT of TiM. Recruitment 
and retention were successful and rates similar to those 
in trials of disease-modifying treatments in MND (such 
as diaphragmatic pacing).38 In addition, we recruited 
patients who were more representative of the typical 
MND population than in other clinical trials.27 39 40 This 
included patients with severe disability and those living 
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at a distance from hospital. Involvement of patient 
groups in the trial design, the low burden of the study 
and participants’ motivations to participate in research 
were the key facilitators of study success. The potential 
barriers to research participation identified (time, fatigue 
and the impact on research on day-to-day life) were not 
a problem in this trial. We recommend that our methods 
and findings be adopted in other trials in MND in order 
to improve recruitment and equality of access. Future 
clinical trials could even use the TiM as a cost-effective, 
low-burden research tool to collect outcome measures.
This was a small study in a single centre using motivated 
patients and staff involved in the development of the 
TiM. Larger trials at other centres may not experience 
the high levels of recruitment and retention seen here. 
Problems with recruitment are not unique to MND: less 
than a third of trials manage to meet recruitment targets 
and half require an extension.41 A sample size of 260 is 
feasible but challenging. The Sheffield MND clinic is one 
of the largest in the UK, and even using very broad inclu-
sion criteria, only approximately half of patients recently 
attending the MDC were eligible to participate. Of these, 
only approximately half responded to an invitation. 
Therefore, for a sample size of 260 and a realistic estimate 
of recruiting 10%–25% of all the patients under the care 
of MND centre, the involvement of MND centres with a 
total caseload of between 1000 and 2500 patients would 
be required (this accounts for one quarter and a half of 
UK centres). Recruitment might be improved with face-
to-face invitations, advertising and the use of national 
MND registries (eg, ref 42) that could even allow patients 
to identify themselves for research even when they cannot 
travel to a research centre.
The main limitation of this study was the difficulty esti-
mating the impact that the TiM system would have on 
a service and healthcare resources. Hardware costs are 
likely to be minimal, particularly if patients used their 
own devices and software costs will depend on factors such 
as the uptake of the service, the capability of the system 
and data storage costs. The nurses’ time diary was not 
completed and it was difficult to differentiate time spent 
providing usual care from the additional work generated 
by the TiM system. Any additional work or time saved will 
vary depending on the MDC set-up and how the indi-
vidual reacts to alerts (discussed in the parallel paper 29) 
but reassuringly the telehealth nurse felt the additional 
work was minimal and she could use the system within 
her current role. Many trials of telehealth employ addi-
tional staff to use the system but this fails to reflect how 
a new system would be used when embedded within an 
established service. Like other trials of telehealth (eg, ref 
43), it would also be challenging to demonstrate a reduc-
tion in health resource use. In this case it is the low levels 
of the most costly encounters (hospital admissions) and 
the complexity of MDC care with highly variable levels of 
health resource use which do not appear to be directly 
linked to quality of care that pose challenges. In addition, 
our parallel paper suggests that any potential impact of 
the TiM on individual patients may vary depending on 
the stage and severity of the disease, meaning single 
outcome measures may fail to capture all relevant impacts 
(eg, improved communication may improve emotional 
QoL for patients early in the disease whereas earlier iden-
tification of physical complications may prolong survival 
in the later stages).29
While it may be feasible to conduct a larger trial of 
telehealth in MND, a traditional RCT may not always be 
the best way to evaluate such a complex intervention.44 
An RCT aims to determine whether, all other factors 
being equal, a specific intervention works at the popu-
lation level. However, a multicentre study would involve 
different MND services and while all MND care centres 
do adhere to the same guidelines.12 13 Their structures 
differ, meaning the impact of the TiM may differ with 
results from one site unlikely to fully predict whether it 
would work in other services. Service-level evaluations 
using non-randomised studies are inevitably less costly, 
quicker and able to recruit in larger cohorts than RCTs 
(all important factors in rare, terminal diseases such as 
MND). However, the limitations of such studies have 
been extensively documented with several published 
examples reminding us of the need to undertake assess-
ments of both benefits and risks of new interventions. 
These include studies in MND, where apparently bene-
ficial therapies subsequently were reported as ineffective 
or even harmful (eg, ref 38). However, there is conflicting 
evidence on the extent by which RCTs and well-designed 
controlled studies differ in this regard.45–48
While the role of non-RCTs in evidence-based medicine 
remains controversial, they are appealing in this type of 
situation where the intervention is perceived as being 
low risk and having modest clinical impact. In terms of 
efficacy, given MDC has been demonstrated to improve 
outcomes, it may be preferable to simply determine 
whether the TiM system can deliver an equivalent service 
to the current usual care, and/or widen access to MDC 
services that are already proven to be beneficial. In addi-
tion, the MRC framework recommends that developing 
and implementing technology is an iterative processes.23 
An RCT would not provide sufficient opportunity to 
change the intervention substantially during the trial 
in response to feedback from centres, advances in tech-
nology and changes to the way MND care is delivered. 
Implementation studies may be better placed to demon-
strate this while also providing the opportunity to demon-
strate some of the complex clinical, professional and 
institutional factors that influence the success or failure 
of such an intervention.44 49 These also enable clinical 
services to test and modify the TiM to increase the like-
lihood of local buy-in, promoting local ‘champions’ who 
witness the successes of new services can deliver persua-
sive arguments to support commissioning of services.50 In 
the case of digitally enabled technology, at both a meth-
odological and health service level it remains uncertain 
what represents a good trial and what evidence is needed 
to enable interventions to be funded and adopted.
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COnCluSIOn
The study suggests that a large-scale evaluation of the 
TiM system would be possible but challenging. This study 
suggests that it could be possible to overcome some chal-
lenges seen in other MND trials (such as recruitment 
and retention). With such diverse clinical settings with 
complex groups of patients, alternative methods of eval-
uating may be more appropriate in generating practical 
and generalisable data and support TiM development 
and implementation.
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